Johnson & Johnson (NYSE: JNJ) said on Thursday it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate. J&J also said it plans to submit an emergency use authorization application to the U.S. Food and Drug Administration (FDA) in February if the data from the study is safe and effective. JNJ’s stocks have advanced just 5% since the beginning of the year and are trading close to all-time highs resistance at $157. Imminent news for the vaccine trials could be a very good catalyst for higher price levels.